Table 2.

Incidence of bone metastases and mortality

	Clodronate (n = 530)	Placebo (n = 539)	Hazard ratio (95% CI)	P value
Bone metastases (all patients)
2 years	19 (3.6%)	35 (6.5%)	0.546 (0.312, 0.954)	0.031
5 years	51 (9.6%)	73 (13.5%)	0.692 (0.484, 0.990)	0.043
Bone metastases (stage II/III)
n	352	357
2 years	16 (3.0%)	32 (6.0%)	0.496 (0.272, 0.975)	0.020
5 years	39 (7.4%)	64 (11.8%)	0.592 (0.398, 0.882)	0.009
Visceral metastases
2 years	39 (7.3%)	47 (8.7%)	0.84 (0.55,1.29)	0.428
5 years	79 (14.9%)	94 (17.4%)	0.84 (0.62,1.13)	0.241
Visceral metastases (stage II/III)
n	352	357
2 years	34 (9.7%)	42 (11.8%)	0.81 (0.52,1.28)	0.372
5 years	64 (18.2%)	81 (22.7%)	0.77 (0.56,1.07)	0.120
Deaths during follow-up (median follow-up, 5.6 years)
All patients	98 (18.5%)	129 (23.9%)	0.768 (0.591, 0.999)	0.048
Stage II/III	82 (23.3%)	110 (30.8%)	0.743 (0.558, 0.989)	0.041

CI, confidence interval.